Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
CorMedix Inc (NASDAQ: CRMD) closed the day trading at $5.70 down -2.31% from the previous closing price of $5.84. In other words, the price has decreased by -$2.31 from its previous closing price. On the day, 0.81 million shares were traded. CRMD stock price reached its highest trading level at $5.97 during the session, while it also had its lowest trading level at $5.62.
Ratios:
For a better understanding of CRMD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.78 and its Current Ratio is at 6.97. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on August 10, 2023, initiated with a Outperform rating and assigned the stock a target price of $6.
On February 17, 2021, Needham started tracking the stock assigning a Buy rating and target price of $31.
On September 29, 2020, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.JMP Securities initiated its Mkt Outperform rating on September 29, 2020, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when Todisco Joseph bought 13,561 shares for $3.74 per share. The transaction valued at 50,718 led to the insider holds 352,839 shares of the business.
DUNTON ALAN W bought 3,000 shares of CRMD for $9,900 on Dec 15 ’23. The Director now owns 15,250 shares after completing the transaction at $3.30 per share. On Dec 14 ’23, another insider, DUNTON ALAN W, who serves as the Director of the company, bought 3,000 shares for $3.45 each. As a result, the insider paid 10,350 and bolstered with 12,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 313667168 and an Enterprise Value of 245726640.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.76, which has changed by 0.10188675 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $7.00, while it has fallen to a 52-week low of $2.57. The 50-Day Moving Average of the stock is 25.12%, while the 200-Day Moving Average is calculated to be 48.95%.
Shares Statistics:
Over the past 3-months, CRMD traded about 613.05K shares per day on average, while over the past 10 days, CRMD traded about 599370 shares per day. A total of 54.94M shares are outstanding, with a floating share count of 53.94M. Insiders hold about 1.89% of the company’s shares, while institutions hold 33.70% stake in the company. Shares short for CRMD as of 1713139200 were 9376942 with a Short Ratio of 15.30, compared to 1710460800 on 7772742. Therefore, it implies a Short% of Shares Outstanding of 9376942 and a Short% of Float of 17.06.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of CorMedix Inc (CRMD).On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.25 and a low estimate of -$0.32, while EPS last year was -$0.24. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.22 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$0.26 and -$1.09 for the fiscal current year, implying an average EPS of -$0.74. EPS for the following year is -$0.1, with 4.0 analysts recommending between $0.55 and -$0.67.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $1.67M. There is a high estimate of $3.7M for the next quarter, whereas the lowest estimate is $200k.
Based on 4 analysts’ estimates, the company’s revenue will be $81.93M in the next fiscal year. The high estimate is $105.75M and the low estimate is $66.95M.
